These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6871660)

  • 21. Age-related changes in CNS-sensitivity to hexobarbital and thiopental in the rat.
    Bolander HG; WahlströmG
    Arch Int Pharmacodyn Ther; 1984 Feb; 267(2):213-23. PubMed ID: 6712356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic aspects on acute tolerance to hexobarbital evaluated with an anesthesia threshold.
    Wahlström G; Bolander HG
    Alcohol; 1985; 2(2):297-301. PubMed ID: 4015850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in cholinergic function in rat brain late in abstinence after chronic barbital treatment.
    Nordberg A; Wahlström G
    Drug Alcohol Depend; 1981 Feb; 7(1):51-61. PubMed ID: 7215155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nerve growth factor (NGF) in rat brain following long-term barbital treatment: relation to convulsions and cognitive function.
    Wahlström G; Archer T; Lärkfors L
    Neurosci Lett; 1992 Mar; 137(1):65-8. PubMed ID: 1625820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GABAergic influences on barbital withdrawal induced convulsions.
    Sandoval MR; Palermo-Neto J
    Gen Pharmacol; 1986; 17(4):431-5. PubMed ID: 3758649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased susceptibility of audiogenic rats to barbital withdrawal convulsions.
    Bourn WM; Garrett RL
    Pharmacol Biochem Behav; 1983 Nov; 19(5):839-41. PubMed ID: 6685882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Studies on the physical dependence liability to guanabenz].
    Kaneto H; Kosaka N; Takasu M; Mino T
    Nihon Yakurigaku Zasshi; 1982 Nov; 80(5):405-15. PubMed ID: 6891939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study of the duration of acute tolerance induced with hexobarbital in male rats.
    Wahlström G
    Pharmacol Biochem Behav; 1998 Apr; 59(4):945-8. PubMed ID: 9586853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interactions between hexobarbital and thiopental in male rats evaluated with an anaesthesia threshold.
    Norberg L; Wahlström G
    Acta Pharmacol Toxicol (Copenh); 1986 Feb; 58(2):96-104. PubMed ID: 3705973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in a hexobarbital anaesthesia threshold in rats induced by repeated long-term treatment with barbital or ethanol.
    Wahlström G
    Psychopharmacologia; 1971; 19(4):366-80. PubMed ID: 5105729
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in convulsion threshold and changes in the action of certain sleep-inducing drugs in hypertensive rats (DOCA/NaCl and SHR).
    Czyzewska-Szafran H
    Acta Physiol Pol; 1980; 31(2):147-52. PubMed ID: 7395539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [General pharmacology of 6-amino-2-fluoromethyl-3-(o-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. I. Effects on the central nervous system (author's transl)].
    Ochiai T; Yamamura M; Kudo Y; Ishida R
    Nihon Yakurigaku Zasshi; 1981 Oct; 78(4):347-57. PubMed ID: 7327455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Central nervous system supersensitivity and withdrawal from long-term treatment with barbital.
    Sandoval MR; Palermo-Neto J
    Neuropharmacology; 1985 Dec; 24(12):1247-51. PubMed ID: 4094660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Withdrawal in the rat after long-term forced oral barbital administration.
    Wahlström G
    Acta Pharmacol Toxicol (Copenh); 1974 Aug; 35(2):131-44. PubMed ID: 4479394
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of alpha-methyl-p-tyrosine on the incidence of spontaneous convulsions observed following barbital withdrawal.
    Morgan WW; Pfeil KA; Gonzales EG
    Neuropharmacology; 1978 Feb; 17(2):115-9. PubMed ID: 565016
    [No Abstract]   [Full Text] [Related]  

  • 36. Maturation-related changes in tolerance development to hexobarbital after short term treatment with diazepam in the rat.
    Korkmaz S; Carlsson S; Wahlström G
    Brain Res; 1993 Jan; 600(2):345-8. PubMed ID: 8435757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of pantogam potentiation of certain effects of hexobarbital and sodium barbital and inhibition of phenamine hyperactivity].
    Avakumov VM; Kovler MA
    Farmakol Toksikol; 1981; 44(1):30-4. PubMed ID: 7262297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat.
    Korkmaz S; Ljungblad E; Wahlström G
    Brain Res; 1995 Apr; 676(2):371-7. PubMed ID: 7614008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of tolerance to chronic barbital treatment in the cerebellar cyclic guanosine monophosphate system and its response to subsequent barbital abstinence.
    Lane SJ; Morgan WW
    J Pharmacol Exp Ther; 1985 Sep; 234(3):569-74. PubMed ID: 2993585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between 1,2--propanediol (propylene glycol) and hexobarbital.
    Osterlind A; Akesson A; Wahlström G
    Acta Pharmacol Toxicol (Copenh); 1979 Sep; 45(3):245-8. PubMed ID: 506748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.